Cargando…
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
Multiple sclerosis (MS) is a progressive, neurodegenerative disease with unpredictable phases of relapse and remission. The cause of MS is unknown, but the pathology is characterized by infiltration of auto-reactive immune cells into the central nervous system (CNS) resulting in widespread neuroinfl...
Autores principales: | Furber, Kendra L, Van Agten, Marina, Evans, Charity, Haddadi, Azita, Doucette, J Ronald, Nazarali, Adil J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053102/ https://www.ncbi.nlm.nih.gov/pubmed/30050377 http://dx.doi.org/10.2147/DNND.S71986 |
Ejemplares similares
-
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015) -
Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2018) -
Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis
por: Yetkin, Mehmet Fatih, et al.
Publicado: (2016) -
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017) -
Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: Is There an Odd One Out?
por: Clapin, Alexis
Publicado: (2012)